[HTML][HTML] COVID-19 infection: the perspectives on immune responses

Y Shi, Y Wang, C Shao, J Huang, J Gan… - Cell Death & …, 2020 - nature.com
Y Shi, Y Wang, C Shao, J Huang, J Gan, X Huang, E Bucci, M Piacentini, G Ippolito
Cell Death & Differentiation, 2020nature.com
More than 100 years since the outbreak of the 1918 influenza pandemic, we now seem to
face another pandemic. The outbreak of the new coronavirus (SARS-CoV-2) infection is
spreading to every continent, forcing us to live with this virus for perhaps a long time.
Scientists and clinicians have learned much of coronavirus disease 2019, COVID-19, and its
pathogenesis [1]: not all people exposed to SARS-CoV-2 are infected and not all infected
patients develop severe respiratory illness. Accordingly, SARS-CoV-2 infection can be …
More than 100 years since the outbreak of the 1918 influenza pandemic, we now seem to face another pandemic. The outbreak of the new coronavirus (SARS-CoV-2) infection is spreading to every continent, forcing us to live with this virus for perhaps a long time. Scientists and clinicians have learned much of coronavirus disease 2019, COVID-19, and its pathogenesis [1]: not all people exposed to SARS-CoV-2 are infected and not all infected patients develop severe respiratory illness. Accordingly, SARS-CoV-2 infection can be roughly divided into three stages: stage I, an asymptomatic incubation period with or without detectable virus; stage II, non-severe symptomatic period with the presence of virus; stage III, severe respiratory symptomatic stage with high viral load [2]. From the point of view of prevention, individuals at stage I, the stealth carriers, are the least manageable because, at least on some occasions, they spread the virus unknowingly: indeed, the first asymptomatic transmission has been reported in Germany [3]. The role of asymptomatic SARS-CoV-2 infected individuals in disseminating the infection remains to be defined.
Among over 1000 patients analyzed in Wuhan, except occasionally in children and adolescence, it infects all the other age groups evenly. About 15% of the confirmed cases progress to the severe phase, although there is a higher chance for patients over 65 to progress into the severe phase [1]. One of the biggest unanswered questions is why some develop severe disease, whilst others do not. Clearly, the conventional wisdom based on overall immunity of the infected patients cannot explain this broad spectrum in disease presentation.
nature.com